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Capicua (CIC) has been implicated in pathogenesis of spinocerebellar ataxia type 1 and cancer inmammals;
however, the in vivo physiological functions of CIC remain largely unknown. Here we show that Cic
hypomorphic (Cic-L-/-) mice have impaired bile acid (BA) homeostasis associated with induction of
proinflammatory cytokines. We discovered that several drug metabolism and BA transporter genes were
down-regulated in Cic-L-/- liver, and that BAwas increased in the liver and serumwhereas bile was decreased
within the gallbladder of Cic-L-/- mice. We also found that levels of proinflammatory cytokine genes were
up-regulated in Cic-L-/- liver. Consistent with this finding, levels of hepatic transcriptional regulators, such
as hepatic nuclear factor 1 alpha (HNF1a), CCAAT/enhancer-binding protein beta (C/EBPb), forkhead box
protein A2 (FOXA2), and retinoid X receptor alpha (RXRa), were markedly decreased in Cic-L-/- mice.
Moreover, induction of tumor necrosis factor alpha (Tnfa) expression and decrease in the levels of FOXA2,
C/EBPb, and RXRa were found in Cic-L-/- liver before BA was accumulated, suggesting that inflammation
might be the cause for the cholestasis in Cic-L-/- mice. Our findings indicate that CIC is a critical regulator of
BA homeostasis, and that its dysfunction might be associated with chronic liver disease and metabolic
disorders.
C
IC is an HMG box-containing transcriptional repressor that is evolutionarily conserved from
Caenorhabditis elegans to humans1. CIC exists as at least two isoforms, CIC-S and CIC-L, which differ
in their amino-terminal regions2. CIC preferentially binds to octameric TGAATGA/GA or TCAATGAA
sequences within target promoters and enhancers, and several CIC target genes have been identified inDrosophila
and mammals3–5. In mammals, CIC has been implicated in cancer progression and pathogenesis of spinocer-
ebellar ataxia type 1 (SCA1). Dozens ofmutations in theCIC gene have been identified in the tissues from patients
with various types of cancers6–8, and the chromosomal translocation generating CIC-DUX4 fusion has been
discovered in Ewing-like sarcomas3. Moreover, PEA3 group genes, the best known CIC target genes, are usually
overexpressed in various types of cancers, suggesting that CIC deficiency could contribute to tumorigenesis and/
or cancer progression through their de-repression9,10. We have previously shown that deficiency of CIC results in
alveolarization defects and overexpression of MMP9 in mouse lung tissues11. On the other hand, CIC interacts
with ATXN1, the causative protein of SCA1, and its paralog ATXN1-Like (ATXN1L), and this interaction
stabilizes these proteins5,11. Haploinsufficiency of CIC alleviates disease severity in SCA1 mice (Atxn1154Q
knock-in mice), suggesting that mutant ATXN1 causes SCA1 in part due to enhanced activity of the CIC/
ATXN1 complex5.
BA is synthesized from cholesterol in hepatocytes by various enzymes including cholesterol 7a-hydroxylase
(CYP7A1), 25-hydroxycholesterol 7a-hydroxylase (CYP7B1), sterol 27-hydroxylase (CYP27A1), and sterol 12a-
hydroxylase (CYP8B1), and stored in the gallbladder. After ingestion of food, bile flows into the duodenum,
where it contributes to the digestion of lipophilic nutrients. BAs are then absorbed from the terminal ileum and
transported back to the liver via the portal vein. This entire process is called enterohepatic circulation of BA.
Defects in excretion of hepatic BA cause cholestatic liver damage and chronic liver diseases due to toxicity of BAs
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and induction of inflammatory response12. Inflammation also can
cause cholestasis through dysregulation of hepatobiliary transport
system. Proinflammatory signaling cascades lead to repressed expres-
sion and activity of several liver-enriched transcription factors and
nuclear receptors, which are essential for maintenance of a large
number of genes involved in detoxification and hepatobiliary trans-
port of BAs and other toxic compounds13,14, thereby disrupting the
enterohepatic circulation of BA.
BA can serve as a ligand for several nuclear receptors. The BA-
mediated activation of farnesoid X receptor (FXR, also known as
NR1H4) facilitates transcription of small heterodimer partner (Shp,
also known asNr0b2), which in turn suppresses the expression of key
genes in BA biosynthesis and Na1-taurocholate cotransporting poly-
peptide (Ntcp, also known as Slc10a1), a transporter mediating BA
uptake from plasma15,16. Therefore, this negative feedback loop main-
tains BA homeostasis in the liver.
In this study, we show that CIC deficiency impairs BAhomeostasis
in mice. We also found that levels of several hepatic transcriptional
regulators, known to regulate expression of drugmetabolism and BA
transporter genes, were markedly reduced, whereas proinflamma-
tory cytokine gene expression was increased in liver of Cic-L-/- mice5.
Thus, we have identified novel roles of CIC in BA homeostasis and,
potentially, inflammatory response.
Results
Serum chemistry for Cic-L-/- mice. To get insight of in vivo physiolo-
gical roles of CIC, we first checked tissue distribution of CIC and
ATXN1L proteins in mice. We found that CIC was expressed in
various types of tissues, except for kidney (Fig. 1), and that ATXN1L
levels decreased in all tested Cic-L-/- tissues (Fig. 1), suggesting that
CIC exists as a complex with ATXN1L in most tissues. Next, we
investigated whether Cic-L-/- mice had metabolic abnormalities by
measuring the levels of serum metabolites in WT and Cic-L-/- mice
at P18, and found that glucose levels were decreased whereas levels of
BA and total bilirubin were significantly increased in sera from Cic-L-/-
mice compared withWT (Table 1). It is also noteworthy that the serum
alanine transaminase (ALT) level, a general parameter indicating liver
insult, was increased in Cic-L-/- mice, though not statistically significant
(Table 1), suggesting that Cic-L-/- mice might have defects in liver
function.
Altered expression of drug metabolism genes in Cic-L-/- liver.
Hepatic expression of CIC proteins and significant alterations in
levels of several serum metabolites in Cic-L-/- mice led us to investi-
gate roles of CIC in liver given its role in a wide variety of metabolic
processes. To examine hepatic gene expression changes caused by
deficiency of CIC, we carried out microarray analysis using liver
total RNA from WT and Cic-L-/- mice at P18 (four mice per each
genotype). A total of 718 differentially expressed genes (DEGs; P ,
0.05) betweenWT and Cic-L-/-mice (405 up-regulated and 313 down-
regulated in Cic-L-/- liver) were identified using an integrative stati-
stical method (Fig. 2a and Table S1). To examine cellular pathways
represented by the DEGs, we performed KEGG pathway enrichment
analysis for the DEGs using DAVID software17. The analysis revealed
that the down-regulated genes most significantly represented those
involved in drug metabolism (also known as xenobiotic metabolism)
(Fig. 2b). Drug metabolism involves a set of enzymatic processes and
transporters that modify and remove toxic chemicals from cells in
three phases. Phase I is conducted by enzymes mediating oxidation,
reduction, or hydroxylation, such as cytochrome P450 enzymes (CYPs),
flavin-containing monooxygenases (FMOs), alcohol dehydrogenases
(ADHs), and aldehyde dehydrogenases (ALDHs). In phase II, phase I
products are conjugated with charged species, such as glutathione,
sulfate, and glucuronic acid mediated by glutathione-S-transferases
(GSTs), sulfotransferases (SULTs), and UDP-glucuronosyltransferases
(UGTs). In phase III, the conjugates can be excreted from cells by a
variety of membrane transporters including multidrug resistance
protein (MRP) family. Proteins involved in drug metabolism act
not only on the pharmaceutical drugs or xenobiotics, but also on
endogenous metabolites including BA to maintain their homeostasis.
Using qRT-PCR, we confirmed the down-regulation of several phase
I and phase II drug metabolism genes in Cic-L-/- liver. Sixteen (84%)
out of the 19 tested genes were significantly down-regulated in Cic-L-/-
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Figure 1 | Tissue distribution of CIC and ATXN1L proteins in mice.Western blot analysis for tissue distribution of CIC and ATXN1L proteins at P18.
Twenty mg of total protein extract was loaded on each lane. KO means Cic-L-/- mouse.
Table 1 | Serum chemistry for 18 day-old WT and Cic-L KO mice
WT Cic-L KO No. of tested animals (WT 5 KO)
Glucose (mg/dL)*** 107.0 6 8.700 53.4 6 8.235 655
Insulin (ng/mL) 0.320 6 0.026 0.285 6 0.006 454
Cholesterol (mM) 5,137.29 6 701.646 5,203.03 6 436.851 454
Triglycerides (nmol/ml) 1.477 6 0.233 0.972 6 0.017 353
Bile acid (mM)** 22.984 6 3.943 49.309 6 5.058 656
Alanine transaminase (U/L) 39.429 6 61.849 61.849 6 11.205 656
Total bilirubin (mg/dL)* 0.312 6 0.044 0.647 6 0.098 656
Direct bilirubin (mg/dL) 0.476 6 0.128 0.745 6 0.190 656
*p,0.05, **p,0.01, ***p,0.001.
www.nature.com/scientificreports
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livers obtained from an independent cohort of animals (Fig. 2c).
Taken together, these data suggest that drug metabolism is likely the
hepatocellular pathway most significantly affected by CIC deficiency.
ImpairedBAhomeostasis inCic-L-/-mice.Given that BA levels were
significantly increased in sera from Cic-L-/- mice (Table 1), and that
some of the drug metabolism genes down-regulated in Cic-L-/- liver,
Cyp2b10, Gstm2, and Sult2a1, are known to be involved in detoxi-
fication and excretion of BAs18,19, we hypothesized that BA homeo-
stasis might be dysregulated in Cic-L-/-mice. To test this hypothesis, we
first checked bile content within gallbladders of 18 day-old WT and
Cic-L-/- mice after overnight fasting. Surprisingly, Cic-L-/- mice showed
dramatically shrunken gallbladders (Figs. 3a and S1), indicating that
they have less bile within the gallbladder in comparison with WT. We
next measured the concentration of hepatic and intestinal BAs as well
as total BA pool sizes inWT and Cic-L-/-mice. A significant increase in
hepatic BA levels was found in Cic-L-/- mice while total BA pool size
was comparable between them (Fig. 3b). These data suggest that CIC
deficiency impairs the enterohepatic circulation of BA, based on our
finding showing accumulation of BAs in serum and liver and dilatory
excretion of bile into gallbladder in Cic-L-/- mice.
Cholestasis can be induced by bile duct malformation; however,
histological analysis of the liver showed that hepatic bile duct forma-
tion is comparable between WT and Cic-L-/- mice (Fig. S2). We then
investigated expression levels of genes implicated in BA biosynthesis
and transport. qRT-PCR analysis revealed that the levels of Cyp7a1,
Cyp27a1, Cyp8b1, and bile acid CoA:amino acid N-acyltransferase
(Baat) were significantly decreased in livers from Cic-L-/- mice com-
pared with WT (Fig. 3c), consistent with the microarray results
(Table S1). To test the possibility that down-regulation of those genes
in Cic-L-/- mice could be due to elevated levels of hepatic BAs, we
checked the level of Shp, a target gene of FXR and a negative regulator
of key genes in BA biosynthesis. The level of Shp mRNA was
increased approximately three-fold in livers of Cic-L-/- mice com-
pared with WT (Fig. 3c). Consistent with this finding, levels of
Ntcp, whose expression can be suppressed by SHP, were also
down-regulated in Cic-L-/- mice (Fig. 3c). To determine the cause
of impaired enterohepatic circulation of BA in Cic-L-/- mice, we
checked hepatic mRNA levels of several basolateral and canalicular
membrane transporters mediating bile flow by qRT-PCR. Among
eight different membrane transporter genes, levels of bile salt export
pump (Bsep, also known as abcb11) and organic anion transporting
polypeptide 2 (Oatp2), which are responsible for excretion of bile
salts into the canaliculi and hepatic uptake of BAs from plasma,
respectively, were significantly decreased in Cic-L-/- mice (Fig. 3d).
Moreover, levels of Mdr2 (also known as Abcb4) and Oatp-b (also
known as Slco2b1) were significantly decreased in Cic-L-/- mice com-
pared withWT (Fig. 3d). Together with the down-regulation ofNtcp
in Cic-L-/- liver (Fig. 3c), these data explain the accumulation of BAs
in serum and liver in Cic-L-/- mice at the molecular level.
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Figure 2 | Down-regulation of drug metabolism genes in Cic-L-/- liver. (a) Heat map showing up- and down-regulated genes in Cic-L-/- mice (KO)
at P18, compared with WT. The numbers in x-axis denote four replicates used in WT and KO. Red and green colors represent increase and decrease in
expression levels of the genes, respectively, from the mean expression levels of the eight replicates. Color bar, gradient of log2-difference of the intensities
from the median intensities. (b) KEGG pathways significantly represented by the up- and down-regulated genes in Cic-L-/- liver. The significance
was represented by -log10(P) where P is the enrichment P-value obtained from the DAVID software. The number of the up- or down-regulated genes
involved in each pathway is shown. (c) qRT-PCR analysis for levels of nineteen phase I and phase II drug metabolism genes in livers from 18 day-old
WT and Cic-L-/- mice (n54,5 per each genotype). *P,0.05, **P,0.01, and ***P,0.001. All error bars show s.e.m.
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Histological analysis of liver tissue did not show apparent hepatic
damages in Cic-L-/-mice (data not shown). However, it is known that
cholestatic liver injury can be induced in the mice with altered BA
homeostasis on a diet containing cholic acid16 and that intraperito-
neal injection of lithocholic acid can induce necrosis of hepatic
cells in the mice with disrupted drug metabolism20,21. To test whe-
ther deficiency of CIC contributes to induction of cholestatic liver
damages, we placed the nursing females on a diet containing 1% (wt/
wt) cholic acid so that the nursing pups will ingest an excess amount
of cholic acid through breast milk during postnatal growth. Under
this condition, about 30% of Cic-L-/- mice showed hepatic injury at
P18, as evidenced by areas of liver necrosis, which was not found in
WT littermates (Fig. S3a). To further ascertain hepatic injury in Cic
mutants fed with cholic acids, we also determined the serum ALT
level and found that it was significantly increased in Cic-L-/- mice
compared withWT (Fig. S3b). Together, these data suggest that CIC
could play a role in protection of the liver from BA toxicity as well as
in BA homeostasis.
Decrease in protein levels of liver-enriched transcription factors
and induction of proinflammatory cytokine gene expression in
Cic-L-/- mice. Many previous studies have shown that expression of
genes involved in drug metabolism is coordinately regulated by
several nuclear receptors and liver-enriched transcription
factors22–30. It is also known that cholestasis is closely associated
with induction of proinflammatory modulators and decreased
expression and activity of hepatic transcriptional regulators13,14. In
order to explain for the suppressed expression of several drug
metabolism genes in liver and impaired BA homeostasis in Cic
deficient mice, we examined hepatic levels of several liver-enriched
transcription factors and nuclear receptors including FOXA2,
HNF1a, C/EBPb, RXRa, HNF4a, and FOXO1 by western blot
analysis using liver total extracts from WT and Cic-L-/- mice at P18.
We found that levels of FOXA2, HNF1a, C/EBPb, and RXRa, but not
HNF4a and FOXO1, were significantly down-regulated in livers of
Cic-L-/- mice (Fig. 4a), suggesting that down-regulation of drug
metabolism genes might result from decreased levels of a subset of
liver-enriched transcription factors and nuclear receptors in Cic-L-/-
mice. Interestingly, their mRNA levels were not significantly altered
in Cic-L-/- mice (Fig. 4b), indicating that levels of these transcrip-
tion factors are down-regulated at the post-transcriptional level. To
validate that the down-regulation of several genes involved in drug
metabolism and BA transport in Cic-L-/- liver was, at least in part,
due to the decreased levels of hepatic transcriptional regulators, we
examined promoter occupancy of FOXA2 and RXRa for their target
genes whose levels were significantly down-regulated in Cic-L-/- liver
(Figs. 2C and 3D). We carried out chromatin immunoprecipitation
(ChIP) using either anti-FOXA2 or anti-RXRa antibody followed by
qPCR for promoter regions that contain binding motifs for either
FOXA2 or RXRa. ChIP-qPCR analyses revealed that less amount of
FOXA2 and RXRa is associated with promoter regions of all the
tested genes (Oatp2, Fmo3, and Ugt2b34 as FOXA2 targets16, and
Cyp2b10 and Sult2a1 as RXRa targets31,32) in liver of Cic-L-/- mice
compared withWT (Fig. S4), suggesting that reduction in the levels of
several hepatic transcriptional regulators leads to decrease in their
promoter occupancy of target genes, thereby contributing to the
down-regulation of a subset of genes mediating drug metabolism
and BA transport in Cic-L-/- mice.
We also checked the levels of proinflammatory cytokine genes to
determine induction of inflammatory response in the liver of Cic-L-/-
mice. The levels of interleukin-6 (Il-6) and Tnfa were significantly
increased in Cic-L-/- mice compared with WT (Fig. 4c), suggesting
that the hepatic cholestasis in Cic-L-/- mice might be associated with
increased inflammatory response. Altogether, these data indicate
that CIC deficiency leads to disruption in BA homeostasis accom-
panied with dramatic decrease in protein levels of several hepatic
transcriptional regulators and induction of proinflammatory cyto-
kine expression.
Decrease in the levels of a subset of hepatic transcription factors
and drug metabolism genes and induction of Tnfa expression
precede hepatic BA accumulation in Cic-L-/- mice. Because inflam-
mation can cause hepatic cholestasis and vice versa, it was not clear
whether the impaired BA homeostasis is the cause or an effect of the
reduced protein levels of FOXA2, HNF1a, C/EBPb, and RXRa, and
up-regulation of proinflammatory cytokine genes in Cic-L-/- liver.
To address this, we assessed levels of FOXA2, HNF1a, C/EBPb,
and RXRa at P10, when levels of hepatic BA and Shp mRNA are
comparable between WT and Cic-L-/- mice (Figs. 5a and 5b). We
found that protein levels of FOXA2, C/EBPb, and RXRa were still
decreased in Cic-L-/- liver compared with WT (Fig. 5c), although the
fold decrease in FOXA2 and C/EBPb protein levels was less dramatic
at P10 than at P18 (Figs. 4a and 5c). These data suggest that hepatic
cholestasis is not the primary cause for the reduction in levels of
FOXA2, C/EBPb, and RXRa in Cic-L-/- mice, but that it could be
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facilitated as hepatic cholestasis develops. HNF1a proteins were not
detectable in livers at P10 under our experimental conditions. Among
eighteen drug metabolism genes with decreased levels in Cic-L-/- liver
at P18 (Fig. 2c), seven were significantly down-regulated and half of
them showed a trend toward down-regulation in livers from 10 day-
old Cic-L-/- mice (Fig. 5d), suggesting that decreased levels of a subset
of hepatic transcription factors are probably associated with the down-
regulation of drug metabolism genes in Cic-L-/- mice. We also checked
hepatic levels of the membrane transporter genes in Cic-L-/- mice at
P10. Among five genes, only Oatp2 andMdr2 levels were significantly
down-regulated in livers of Cic-L-/- mice at P10 (Fig. 5e), suggest-
ing that decreased levels of Ntcp, Bsep, and Oatp-b might critically
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genes in livers from 10 day-old WT and Cic-L-/- mice (n53 per each genotype). *P,0.05 and ***P,0.001. All error bars show s.e.m. (e) qRT-PCR
analysis for levels of membrane transporter genes in livers from 10 day-old WT and Cic-L-/- mice (n53 per each genotype). *P,0.05 and **P,0.01. All
error bars show s.e.m. (f) qRT-PCR analysis for levels of Il-1b, Il-6, and Tnfa using liver total RNAs prepared from 10 day-oldWT andCic-L-/-mice (n54
per each genotype). *P,0.05. All error bars show s.e.m.
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contribute to the disruption in BA homeostasis in Cic-L-/- mice
at P18. Finally, we examined the expression of proinflammatory
cytokine genes in liver of Cic-L-/- mice at P10. We found that Tnfa
levels were significantly increased in Cic-L-/- mice compared with
WT (Fig. 5f), suggesting that inflammatory response was already
induced in Cic-L-/- liver at P10, but amplified during cholestasis,
based on more dramatic and significant fold increase in the levels
of proinflammatory cytokine genes in Cic-L-/- liver at P18 than at
P10 (Figs. 4c and 5f). Taken together, these data suggest that
CIC deficiency induces proinflammatory signaling cascades in
liver, thereby perturbing BA homeostasis.
Discussion
In this study, we show that CIC plays a critical role in regulating
hepatic inflammatory response and BA homeostasis. Based on our
findings, we propose a model to explain how CIC disrupts such pro-
cesses in mice (Fig. S5). Loss of CIC triggers hepatic proinflammatory
signaling cascades that decrease the protein levels of liver-enriched
transcription factors and nuclear receptors including FOXA2, C/
EBPb, and RXRa, thereby causing down-regulation of several drug
metabolism genes in Cic-L-/- mice before BA accumulates in the liver.
Through these processes, prolonged induction of proinflammatory
cytokines could eventually perturb BA homeostasis in Cic-L-/- mice.
Under cholestatic conditions, proinflammatory signaling is further
induced and amplified, and activity of several liver-enriched transcrip-
tion factors and nuclear receptors including FOXA2, HNF1a, C/
EBPb, and RXRa might become weaker due to a greater reduction
in their protein levels and nuclear exclusion14. These changes, in turn,
further alter drug metabolism pathways and BA homeostasis in Cic-
L-/- mice through more significant down-regulation of larger number
of genes that are cooperatively regulated by liver-enriched transcrip-
tion factors and nuclear receptors.
It is known that inflammation-induced cholestasis is mediated by
cholestatic effects of bacterial endotoxins such as lipopolysaccharides
(LPS) and/or LPS-induced proinflammatory cytokines33. The liver is a
major site of the removal of bacteria and endotoxins from systemic
circulation. Kupffer cells, the hepatic resident macrophages, take up
bacteria and endotoxins, and are stimulated to release proinflamma-
tory cytokines such as IL-1b, IL-6, and TNFa. The produced cytokines,
in turn, trigger intracellular inflammatory signals in hepatocytes, lead-
ing to impairment in bile formation, and accumulation of BAs and
toxins in liver and serum through down-regulation of hepatic trans-
port systems involved in BA uptake and excretion, as well as down-
regulation of phase I and phase II detoxification systems13,34. In this
respect, our data suggest that Cic-L-/-mice might have inflammation-
induced cholestasis. However, it remains unknown how CIC defi-
ciency induces a subset of proinflammatory cytokines, such as TNFa,
in liver. Given that intrahepatic proinflammatory cytokine synthesis
is mediated mainly by Kupffer cells33, CIC might be involved in
regulation of proinflammatory cytokine gene expression in macro-
phages. It has been reported that TNFa gene contains ETS transcrip-
tion factor binding sites in the promoter region35. In addition,
Ras-induced proinflammatory cytokine production is known to be
dependent on MAPK/ETV4 pathway36. Since CIC represses Etv4
expression in alveolar macrophage cells11, deficiency of CIC might
contribute to up-regulation of proinflammatory cytokine genes, such
as Tnfa, through de-repression of Etv4 in hepatic macrophages. It is
noteworthy that up-regulation of Etv4 levels was found in liver of
Cic-L-/- mice at P18 using qRT-PCR (Fig. S6), although it did not
appear in microarray results (Table S1). Taken together, investiga-
tion on functions of CIC in macrophages and other immune cells
involved in proinflammatory cytokine production would be import-
ant in uncovering the molecular mechanism for regulation of inflam-
matory response by CIC.
Our analysis of serum metabolites also revealed hypoglycemia in
Cic-L-/- mice. According to the KEGG pathway enrichment analysis,
genes involved in metabolism for several different kinds of amino
acids were significantly enriched among the down-regulated genes in
Cic-L-/- liver (Fig. 2b). Indeed, we confirmed significant down-regu-
lation of nine amino acid metabolism genes (out of fifteen) in Cic-L-/-
liver by qRT-PCR using liver total RNA prepared from an independ-
ent cohort of animals (Fig. S7a). We also found that levels of glucose
6-phosphatase (G6pc) and phosphoenolpyruvate carboxykinase
(Pepck), key genes mediating gluconeogenesis, were not significantly
altered inCic-L-/-mice compared withWT (Fig. S7a), consistent with
themicroarray results (Table S1). Given that amino acids can be used
as carbon precursors in gluconeogenesis37 (Fig. S7b), and that down-
regulation of genes encoding enzymes of amino acid catabolism are
associated with hypoglycemia in mice38, the decreased levels of
amino acid metabolism genes might contribute to hypoglycemia in
Cic-L-/- mice. Further studies on the molecular mechanism under-
lying hypoglycemia in Cic-L-/- mice will demonstrate critical roles of
CIC in various metabolic processes.
Since the long isoform of CIC (CIC-L) harbors a unique amino-
terminal region of about 900 amino acids long, the two isoforms of
CIC, CIC-L and CIC-S, might have differential roles. It was recently
reported that CIC-S, but not CIC-L, predominantly exists in the
cytoplasm and regulates cytosolic citrate metabolism through inter-
acting with ATP citrate lyase (ACLY)39, suggesting differential func-
tions of the CIC isoforms in mammals. Given that CIC-L expression
is completely abolished whereas a small amount of CIC-S is still
expressed in Cic-L-/- mice5 (Fig. 1), it is unclear whether the defects
observed in Cic-L-/- mice reflect a CIC-L specific requirement, a
partial loss of CIC-S, or a reduction of total CIC activity. To better
understand molecular pathways for the CIC-mediated biological
processes including regulation of BA homeostasis and glucose meta-
bolism, comparative studies on molecular characteristics and in vivo
functions of CIC isoforms will be required.
Although the functions of CIC have mostly been investigated in
neurodegeneration and cancer, this study provides new insight into
the critical role of CIC in normal liver function andmetabolism. Our
findings not only suggest that CIC is important in regulation of BA
homeostasis and hepatic inflammatory response, but also raise the
possibility that CIC dysfunction might be associated with pathogen-
esis of chronic liver disease and metabolic disorders in humans.
Methods
Ethics Statement. All experimental procedures and animal care were performed in
accordance with the guidelines approved by the ethics committee in Pohang
University of Science and Technology (POSTECH).
Mice. Generation of Cic-L-/- mice was described previously5. Mice were backcrossed
for more than 10 generations onto C57BL/6J background. Animals were maintained
in a pathogen-free animal facility under standard 12 hr light/12 hr dark cycle. Mice
were fed standard rodent chow andwater ad libitum. For the experiments to study the
effect of cholic acid diet on liver functions in Cic-L-/- mice, the normal chow was
replaced with 1% cholic acid-supplemented chow (Purina, Bethlehem, PA) a day
before delivery. In all the experiments except for microarray analyses, mice were
fasted overnight, then anesthetized with isoflurane before collecting tissue and serum
samples. All procedures were approved by the POSTECH Institutional Animal Care
and Use Committee (IACUC).
Serum Chemistry. Blood samples were collected from 18 day-old mice by heart
puncture using 26G 1/2 needles. After blood clot formation, samples were centrifuged
for 30 min at 3,000 rpm at 4uC. Supernatants were collected to new tubes and used for
subsequent experiments. Serum glucose levels were measured by a glucometer.
Insulin levels were determined by mouse insulin EIA (ALPCO, Salem, NH). Levels of
serum triglyceride, cholesterol, alanine transaminase (ALT), and bilirubin were
measured using Triglyceride Quantifcation Colormetic/Fluorometric Kit (Biovision,
Milpitas, CA), Total Cholesterol Assay Kit (Cell biolabs, San Diego, CA),
EnzyChromTM Alanine Transaminase Assay Kit (Bioassay system, Hayward, CA),
and QuantiChromTM Bilirubin Assay Kit (Bioassay systems, Hayward, CA),
respectively, according to the manufacturers’ instructions.
BAMeasurement.The concentration of BAswasmeasured using Diazyme Total Bile
Acids Assay kit (Diazyme Laboratories, Poway, CA) according to the manufacturer’s
instructions. For measurement of hepatic BA levels, median lobes of liver were used.
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For determination of total BA pool size, the whole liver tissue, intact gallbladder, and
small intestine were collected in one tube and subjected to BA measurement.
RNA Extraction and Quantitative Reverse Transcription-Polymerase Chain
Reaction (qRT-PCR). Liver tissues were dissected, flash-frozen in liquid nitrogen,
and stored at 280uC until RNA preparation. Total RNA was extracted using Trizol
reagent (Invitrogen, Carlsbad, CA), then two to three mg of total RNA was subjected
to cDNA synthesis using GoScriptTM Reverse Transcription System (Promega,
Madison, WI) according to the manufacturer’s instructions. Primers used for qRT-
PCR are listed in Table S2. SYBRGreen real-time PCRmastermix (TOYOBO,Osaka,
Japan) was used for PCR reactions.
Microarray Analysis. Gene expression profiles for four replicates of liver tissues
obtained from independent 18 day-old WT and Cic-L-/- mice were generated using
IlluminaMouseRef-8 v2.0 Expression BeadChip (Illumina, San Diego, CA) including
26,821 probes corresponding to 18,016 annotated genes. The probes were annotated
using Manifest file from Illumina. Total RNA (500 ng) was isolated from liver tissues
using RNeasyMini Kit (Qiagen, GmbH, Germany). RNA integrity number (RIN)was
measured using an Agilent 2100 Bioanalyzer (RIN. 9 in all samples). According to
the Illumina protocols, RNA was reverse transcribed and amplified, in vitro
transcription was carried out to prepare cRNA, and the cRNAswere hybridized to the
array and then labeled with Cy3-streptavidin. The fluorescent signal on the array was
measured with a BeadStation 500 System.
Identification of Differentially Expressed Genes (DEGs). The log2-intensities were
first normalized using the quantile normalization method40. The probes were
annotated using Lumi 1.8.3. The expressed genes were identified as previously
described41. To identify DEGs, an integrative statistical hypothesis testing previously
reported was applied to the normalized log2-intensities41. Briefly, both t-test and log2-
median-ratio test were performed to calculate T values and log2-median-ratios for all
genes. Empirical distributions of the null hypothesis (a gene is not differentially
expressed) were estimated by performing random permutations of the samples and
then applying the Gaussian kernel density estimation method42 to T values and log2-
median-ratios resulted from the random permutations. The adjusted P-values of each
gene for the individual tests were then computed by the two-tailed test using their
empirical null distributions and combined using Stouffer’s method to calculate the
overall adjusted P-value43. Finally, the DEGs were selected as the ones with the overall
P,0.05 and absolute log2-fold-changes . 0.43 (1.35-fold), the mean of 2.5th and
97.5th percentiles of the null distribution of log2-fold-changes.
Generation of Rabbit Polyclonal Antibodies for CIC and ATXN1L. Bacterially
expressed C-terminal region (214 amino acids) of CIC44 was used to generate rabbit
polyclonal anti-CIC serum. For generation of polyclonal anti-ATXN1L
antibody, rabbits were immunized with the peptide of 39 amino acids
corresponding to the C-terminus of mouse ATXN1L protein
(SFQRFSMQGEEARAAMLRPSFIPQEVKLSIEGRSNAGK).
Western BlotAnalysis. Liver tissues were homogenized and sonicated in RIPAbuffer
(50 mM Tris (pH 7.4), 150 mM NaCl, 0.5% Sodium deoxycholate, 0.1% SDS, 1%
Triton X-100) containing protease and phosphatase inhibitors and incubated on ice
for 15 min. After centrifugation at 13,300 rpm for 15 min, the supernatant was taken
and 20,25 mg of that was used for sample preparation. Protein samples were loaded
on tris-glycine SDS-PAGE gel and transferred to Trans-Blot nitrocellulosemembrane
(Bio-Rad, Hercules, CA). Antibodies used for western blot analyses are as follows:
anti-CIC (151000 dilution, rabbit), anti-ATXN1L (15500 dilution, rabbit), anti-
RXRa (sc-553, 152000 dilution, rabbit), anti-HNF1a (sc-10791, 15500 dilution,
rabbit), anti-FOXA2 (sc-6554, 15500 dilution, goat), anti-C/EBPb (sc-150, 151000
dilution, rabbit), anti-HNF4a (sc-8987, 15500 dilution, rabbit), anti-FOXO1 (sc-
11350, 15500 dilution, rabbit), and anti-b-actin (sc-47778, 155000 dilution, mouse).
All antibodies, except for anti-CIC and anti-ATXN1L antibodies, were purchased
from Santa Cruz Biotechnology (Dallas, TX). The band intensities were quantified
using ImageJ.
Liver Histology. Liver tissues from 18 day-old WT and Cic-L-/- mice were fixed in
10% formalin and paraffin-embedded before sectioning. The tissues were cut into
6 mm sections, and sections were deparaffinized and dehydrated by using xylene,
100% ethanol, and 95% ethanol sequentially. They were washed by distilled water and
stained with hematoxylin and eosin (Sigma, St. Louis, MO).
Chromatin Immunoprecipitation (ChIP).The liver tissue was chopped with a razor
more than 20 times and crosslinked in 1% formaldehyde for 12 min with constant
shaking then rinsed with cold PBS twice. After centrifugation for 5 min, the pellet was
resuspended in Buffer A (100 mMTris pH 9.4, 1X protease inhibitor cocktail (Roche,
Basel, Switzerland), Buffer 1 (10 mMHEPES, 10 mM EDTA, 0.5 mM EGTA, 0.25%
Triton-X, 1X protease inhibitor cocktail), and Buffer 2 (10 mMHEPES, 0.2 M NaCl,
1 mMEDTA, 0.5 mMEGTA, 1X protease inhibitor cocktail), successively. Tenmg of
liver lysate was resuspended in 100 ml of nuclei lysis buffer (5 mM Tris pH 8.1,
10 mM EDTA, 1% SDS, 1X protease inhibitor cocktail) and sonicated. After
microcentrifugation, the supernatant was pre-cleared with protein G agarose
(Millipore, Billerica, MA), diluted 153 with dilution buffer (16.7 mM Tris pH 8.1,
167 mM NaCl, 1.2 mM EDTA, 0.01% SDS, 1.1% Triton-X, protease inhibitor), and
divided into aliquots. One and a half mg of anti-FOXA2 antibody (sc-6554, Santa Cruz
Biotechnology, Dallas, TX) or anti-RXRa antibody (sc-553, Santa Cruz
Biotechnology, Dallas, TX) was added to each aliquot of chromatin and incubated on
a rotating platform overnight at 4uC. The chromatin and antibody mixtures were
further incubated with protein G agarose for 2–4 h at 4uC. After extensive washing,
bound chromatins were eluted twice by elution buffer (0.5% SDS and 0.1MNaHCO3)
and reverse-crosslinked with 200mM NaCl for at least 4 h at 65uC. Proteins were
digested by proteinase K and DNA was purified by AccuPrep Gel Purification Kit
(Bioneer, Daejeon, Korea). For quantification of the relative enrichment of FOXA2
and RXRa targets in the immunoprecipitated DNA fragments, quantitative real-time
PCR was performed. The FOXA2 and RXRa binding sites in promoter regions of the
tested genes were predicted using PROMO website45, and the primers were designed
to amplify promoter regions harboring one of the putative binding motifs for either
FOXA2 or RXRa. The primer sequences are listed in Table S2.
Statistical Analysis. For statistical analysis, all experiments were performed more
than three times independently. Statistical analyses were carried out using the Student
t-test (two-tailed, two-sample unequal variance). All data were expressed as the mean
6 standard error. A p-value less than 0.05 was considered as significant.
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